Glaxosmithkline Pharmaceuticals Share Price

Glaxosmithkline Pharmaceuticals Investment Rating

• Master Rating:

• Glaxosmithkline Pharms. has an operating revenue of Rs. 3,380.52 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 24% is great, ROE of 63% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 80 which is a GOOD score indicating consistency in earnings, a RS Rating of 29 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 113 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.